Wisconsin Capital Management LLC Raises Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Wisconsin Capital Management LLC lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 26.1% during the second quarter, Holdings Channel.com reports. The fund owned 9,725 shares of the medical equipment provider’s stock after acquiring an additional 2,010 shares during the period. Intuitive Surgical accounts for approximately 2.2% of Wisconsin Capital Management LLC’s holdings, making the stock its 20th biggest holding. Wisconsin Capital Management LLC’s holdings in Intuitive Surgical were worth $4,326,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of ISRG. Ridgewood Investments LLC purchased a new stake in Intuitive Surgical in the second quarter valued at approximately $26,000. Creekmur Asset Management LLC boosted its holdings in shares of Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares during the last quarter. Delos Wealth Advisors LLC raised its holdings in shares of Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 57 shares during the last quarter. LRI Investments LLC purchased a new position in Intuitive Surgical during the first quarter valued at approximately $30,000. Finally, Able Wealth Management LLC acquired a new position in shares of Intuitive Surgical in the 4th quarter valued at $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock traded up $5.46 on Monday, reaching $492.63. The company had a trading volume of 1,097,700 shares, compared to its average volume of 1,521,579. The firm’s 50 day moving average price is $454.69 and its two-hundred day moving average price is $414.94. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $493.97. The firm has a market cap of $175.06 billion, a PE ratio of 88.92, a PEG ratio of 5.43 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the previous year, the company earned $1.18 earnings per share. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,056 shares of company stock worth $25,276,044. 0.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ISRG shares. Truist Financial lifted their price target on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Stifel Nicolaus increased their target price on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. Citigroup boosted their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Morgan Stanley increased their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.